Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.31 (
beta-glucuronidase
)
7,680
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Intestinal bacterial beta-glucuronidases are capable of retoxifying compounds that have been detoxified by liver glucuronidation and are also known to accelerate colon cancer invasion and metastasis. In this study, fucoxanthin extracted from the microalga Phaeodactylum tricornutum was investigated for its inhibitory activity against Escherichia coli
beta-glucuronidase
and DLD-1 cancer cells.
Fucoxanthin
inhibited
beta-glucuronidase
in a concentration-dependent manner with an IC50 value of 2.32 mM and a mixed inhibition type.
Fucoxanthin
had more potent inhibitory activity on
beta-glucuronidase
at 37 degrees C and in alkaline conditions.
Fucoxanthin
also inhibited the
beta-glucuronidase
activity of DLD-1 cancer cells at a concentration of 20-50 microM. The presence of
beta-glucuronidase
and substrate in the medium decreased the inhibitory activity of fucoxanthin against DLD-1 cancer cells. Therefore, microalgal fucoxanthin might prevent colon cancer because of its strong
beta-glucuronidase
inhibitory activity and could be utilized as a novel functional ingredient of food and pharmaceutical supplements.
...
PMID:Application of microalgal fucoxanthin for the reduction of colon cancer risk: inhibitory activity of fucoxanthin against beta-glucuronidase and DLD-1 cancer cells. 2523 Apr 93